# Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat

> **NCT03992014** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Cholestasis

## Interventions

- **DRUG:** Linerixibat tablet
- **DRUG:** [14C]-linerixibat intravenous infusion
- **DRUG:** Linerixibat oral solution

## Key facts

- **NCT ID:** NCT03992014
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-08
- **Primary completion:** 2019-08-26
- **Final completion:** 2019-08-26
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992014, "Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03992014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*